TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34872341
Drug: Combination-therapy group
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-therapy group
Study: 39616189
Drug: Alteplase treatment
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase treatment
Study: 37823469
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment
Study: 36309950
Drug: Carbidopa 100
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa 100 mg with 100 mg IR levodopa without entacapone
Study: 32907635
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days
Study: 36692418
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every 2 weeks
Study: 35057579
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL baobab aqueous extract (BAE)
Study: 35764955
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg AEO BID
Study: 35764955
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg AEO BID
Study: 32690536
Drug: Oral suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suvorexant (20 mg) once daily starting the night after extubation
Study: 34861745
Drug: Peri-articular injection
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular injection with saline erector spinae plane block
Study: 32063238
Drug: Simple reminiscence
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple reminiscence intervention program (10 weekly sessions lasting 2 hours each)
Study: 33341707
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose nab-paclitaxel (MD220) 220 mg/m2
Study: 32989872
Drug: Spironolactone-pioglitazone-metformin (SPIOMET)
Normalized name: metformin / pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone-pioglitazone-metformin (SPIOMET)
Study: 32926748
Drug: Irsogladine maleate
Normalized name: maleate
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine maleate (IM) 4 mg/day for 12 weeks
Study: 39045819
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (Control)
Study: 33439250
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (closed reduction and cast immobilization)
Study: 35341362
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/mL
Study: 35341362
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg/mL
Study: 32987199
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 0.5 mg/kg
Study: 32987199
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 2.0 mg/kg
Study: 32987199
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 3.0 mg/kg
Study: 33822385
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa (0.5, 2.0, or 3.0 mg/kg) administered 3 times per week
Study: 33822385
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa (dose-normalized exposure)
Study: 33822385
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa (dose-normalized exposure across BMI categories)
Study: 33244316
Drug: MVA recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA recombinant vaccine expressing HIV-B antigen (MVA-B) via transcutaneous route
Study: 36526794
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg/kg)
Study: 39236052
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX)
Study: 34188144
Drug: Inefficient arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inefficient arsenic metabolism (%iAs) among never-smokers
Study: 34188144
Drug: Inefficient arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inefficient arsenic metabolism (%MMA) among never-smokers
Study: 34188144
Drug: Efficient arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficient arsenic metabolism (%DMA) among never-smokers
Study: 34188144
Drug: Inefficient arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inefficient arsenic metabolism (%iAs) among ever-smokers
Study: 34188144
Drug: Inefficient arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inefficient arsenic metabolism (%MMA) among ever-smokers
Study: 34188144
Drug: Efficient arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficient arsenic metabolism (%DMA) among ever-smokers
Study: 37697666
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy alone
Study: 32170589
Drug: Inpatient pharmaceutical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient pharmaceutical care (medication reconciliation, daily pharmacist visits, discharge counseling and education by 2 certified pharmacists)
Study: 32170589
Drug: Inpatient pharmaceutical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient pharmaceutical care
Study: 33646060
Drug: PRP-FG dressing
Normalized name: FG-2216
DrugBank: FG-2216 (DB08687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-FG dressing plus oral vitamin E and C
Study: 32876328
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 mcg
Study: 38247384
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group)
Study: 35565689
Drug: PFO‐SM (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFO‐SM (1% PFO, 180 mL/serving)
Study: 36320174
Drug: Betahistine 24
Normalized name: betahistine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 24 mg every 12 hours for 90 days
Study: 36320174
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets every 12 hours for 90 days
Study: 35587408
Drug: Dialectical Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behavior Therapy for Adolescents (DBT-A)
Study: 34694249
Drug: US-guided steroid
Normalized name: Antiinflammatory preparations, non-steroids for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided steroid injection targeting both subcompartments (APL and EPB)
Study: 34694249
Drug: US-guided steroid
Normalized name: Antiinflammatory preparations, non-steroids for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided steroid injection targeting the EPB subcompartment alone
Study: 32677876
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1 × 10^7 cells)
Study: 32677876
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (2 × 10^7 cells)
Study: 32677876
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (5 × 10^7 cells)
Study: 33751917
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection of Dextranomer/Hyaluronic Acid (Dx/HA)
Study: 39738721
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone
Study: 34115851
Drug: ZTL-101 (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZTL-101 (sublingual cannabinoid extract)
Study: 37705972
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids
Study: 616497272
Drug: Intravenous etomidate
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous etomidate alone (group E)
Study: 37254209
Drug: Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy
Study: 32901255
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg/day
Study: 37058788
Drug: Standard treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments
Study: 33159976
Drug: ACT-539313 200
Normalized name: ACT-541468
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACT-539313 200 mg b.i.d.
Study: 35656824
Drug: Ticagrelor‐aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor‐aspirin
Study: 32475444
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 200 mg/kg chitosan (CS200)
Study: 35291272
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch 2 (RS2) at doses of 10, 15, and 20 g/d
Study: 35291272
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RS2 and sugarcane bagasse at doses of 20, 25, and 30 g/d
Study: 37315099
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy (MCT)
Study: 35775872
Drug: Dysport +
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport + Profhilo gel
Study: 32732105
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dinoprostone vaginally
Study: 32415472
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a prescribed dose of 36.25 Gy in 5 fractions, twice a week
Study: 38206151
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control)
Study: 39555827
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment
Study: 34635989
Drug: Vilaprisan 15
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 15 mg single dose
Study: 34635989
Drug: Vilaprisan 1
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 1 mg/day for 28 days
Study: 34635989
Drug: Vilaprisan 5
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan 5 mg/day for 28 days
Study: 35343844
Drug: Medication identification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication identification device (intervention unit)
Study: 35343844
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication administration (control unit)
Study: 39169298
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis
Study: 37414440
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy
Study: 36151961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of transcervical Foley catheter and sublingual misoprostol
Study: 36151961
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol alone
Study: 35871058
Drug: MND-2119 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MND-2119 2 g/day
Study: 35871058
Drug: MND-2119 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MND-2119 4 g/day
Study: 33092901
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution
Study: 35093013
Drug: Atogepant 10
Normalized name: atogepant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 10 mg
Study: 35093013
Drug: Atogepant 60
Normalized name: atogepant 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 60 mg
Study: 34521260
Drug: Atogepant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant (all doses)
Study: 39226070
Drug: Semaglutide, 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide, 2.4 mg
Study: 35904063
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine
Study: 37408018
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Control)
Study: 36054562
Drug: Levodopa/carbidopa 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 400/100 mg plus opicapone 50 mg
Study: 36054562
Drug: Levodopa/carbidopa 500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 500/125 mg without opicapone
Study: 33518452
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 2 atm absolute for 2 hours × 20 sessions
Study: 38961397
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT)
Study: 35106809
Drug: Nebulised unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised unfractionated heparin (UFH)
Study: 38227308
Drug: Placebo (intravenous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous)
Study: 33223425
Drug: RestoreX Penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: RestoreX Penile Traction Therapy (PTT)
Study: 34266853
Drug: No surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgery as part of multimodality treatment
Study: 36251376
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement
Study: 32921367
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment of nonculprit lesions
Study: 35294908
Drug: Low concentration/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration/dose groups (370-0.7, 300-1.0, and 300-0.9)
Study: 35294908
Drug: Low injection
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low injection rate groups (2-370 and 2-350)
Study: 35294908
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard contrast agent protocol)
Study: 33858011
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis oil containing 160/40 mg/ml cannabidiol/tetrahydrocannabinol (CBD/THC) for 8 weeks
Study: 34241691
Drug: Non-TNF biologics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-TNF biologics
Study: 33142537
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg Mn
Study: 33142537
Drug: 20 and
Normalized name: zinc pyrithione 20 MG/ML [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 and 30 mg/kg Mn and 5 × 10^9 CFU/kg BS
Study: 35320424
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy
Study: 36544645
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg remimazolam tosylate
Study: 36544645
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg remimazolam tosylate
Study: 36544645
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg remimazolam tosylate
Study: 37728142
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) only
Study: 34090464
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (100 mg/kg IV, 3 doses: 2 intraoperative and 1 postoperative)
Study: 36131349
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment
Study: 35201518
Drug: Inflawell® syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflawell® syrup (Boswellia extract formulation enriched for boswellic acids)
Study: 38285446
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine
Study: 34261044
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT)
Study: 38419049
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment (ACT)
Study: 36472389
Drug: Whole-brain radiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiation therapy (WBRT)
Study: 35148378
Drug: Best-available therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best-available therapy
Study: 32318268
Drug: High-dose meropenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose meropenem
Study: 32291607
Drug: Thick-needle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick-needle therapy (TNT)
Study: 32291607
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (AT)
Study: 34959111
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz repetitive transcranial magnetic stimulation (rTMS) treatment twice a week
Study: 32108262
Drug: Juçara group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juçara group (5 g lyophilized juçara)
Study: 32108262
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (5 g of maltodextrin)
Study: 35599921
Drug: Betaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (2.5 g·d‐1)
Study: 37422602
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose albumin (1.5 g/kg at diagnosis and 1 g/kg on day three, infused over six hours)
Study: 37422602
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose albumin (0.75 g/kg at diagnosis and 0.5 g/kg 48 hours later, infused over six hours)
Study: 37422602
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose albumin
Study: 32358661
Drug: Peptide (Prostrolane®)
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide (Prostrolane®) injection
Study: 38839388
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group)
Study: 39424559
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT)
Study: 33858696
Drug: Stress taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress taper fixation
Study: 35575751
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy
Study: 32418846
Drug: Alpha Lipoic
Normalized name: Alpha Lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Lipoic Acid (ALA) 1200 mg daily
Study: 35842566
Drug: EOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOX plus aspirin (150 mg daily)
Study: 33735709
Drug: Baclofen 30
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 30 mg/day
Study: 32027206
Drug: Visual Art
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visual Art Therapy (VAT)
Study: 32754150
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with 5 mg iron daily for 4 months starting at age 7.5 months
Study: 32754150
Drug: Anemia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia and serum transferrin receptor at time of vaccination
Study: 38334953
Drug: Aspirin challenge
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin challenge
Study: 34111810
Drug: Algorithm combining
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm combining ICD codes and FVIII/FIX activity <0.4 IU/ml
Study: 36436423
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy (NET)
Study: 35351037
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT), one session per week for 3 to 4 months
Study: 35763229
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (CET)
Study: 39656951
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET)
Study: 33356994
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 100% of basal rate
Study: 33356994
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 150% of basal rate
Study: 33356994
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion rate effect on AUCRd
Study: 39334129
Drug: Heparin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin monotherapy
Study: 36351459
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus a high-dose infusion for 2-4 hours after PCI
Study: 35083337
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training in municipality setting (1 hour, twice weekly for 12 weeks)
Study: 35083337
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training in hospital setting (1 hour, twice weekly for 12 weeks)